Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Tenax a consensus recommendation of Moderate Buy (1 sell, 4 buy, 1 strong buy) with an average 1‑year price target of $29.67, and several firms recently raised targets (Cantor Fitzgerald $35, Guggenheim $34).
• TENX stock traded around $14.88 with a market cap of about $256 million and a 52‑week range of $4.63–$18.38; the company reported an EPS of −$0.38, beating expectations (−$1.26) while analysts forecast roughly −$0.88 EPS for the year.
• Tenax is a clinical‑stage specialty pharmaceutical company developing sustained‑release local anesthetic formulations to extend postoperative analgesia and reduce opioid use, and institutional ownership is low (~1.67%) though several funds (including Goldman Sachs) recently initiated small positions.

Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $29.6667.

Several equities research analysts have recently issued reports on TENX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Tenax Therapeutics in a research note on Monday, December 22nd. Cantor Fitzgerald initiated coverage on shares of Tenax Therapeutics in a research note on Tuesday, March 17th. They issued an "overweight" rating and a $35.00 price target on the stock. William Blair reaffirmed an "outperform" rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. Guggenheim raised their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a research note on Monday, March 16th. Finally, Lifesci Capital raised shares of Tenax Therapeutics to a "strong-buy" rating in a research note on Thursday, March 12th.

Tenax Therapeutics Stock Down 0.9%

TENX stock opened at $14.88 on Tuesday. The company's 50-day simple moving average is $13.34 and its 200-day simple moving average is $10.99. Tenax Therapeutics has a 52-week low of $4.63 and a 52-week high of $18.38. The firm has a market cap of $255.91 million, a P/E ratio of -11.19 and a beta of 1.19.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.88. On average, analysts anticipate that Tenax Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Letko Brosseau & Associates Inc. purchased a new position in Tenax Therapeutics in the 4th quarter valued at about $130,000. Virtu Financial LLC purchased a new position in Tenax Therapeutics in the 3rd quarter valued at about $92,000. Corient Private Wealth LLC purchased a new position in Tenax Therapeutics in the 4th quarter valued at about $151,000. Quadrature Capital Ltd purchased a new position in Tenax Therapeutics in the 4th quarter valued at about $252,000. Finally, Goldman Sachs Group Inc. purchased a new position in Tenax Therapeutics in the 4th quarter valued at about $273,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company's proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax's lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.